1984 Volume 32 Issue Supplement9 Pages 638-650
Diffusion into human prostatic fluids and clinical evaluation of AC-1370, a new parenterally active cephalosporin antibiotic, were performed and the following results were obtained:
(1) The average diffusion into human prostatic fluid was 0.88 μg/ml (n=3) at 1 hour after one shot I. V. administration of 1 g, the average ratio of the diffusion v. s. serum level being 1.4%.
(2) Seven patients with acute simple pyelonephritis were treated with AC-1370 at a daily dose of 1 to 2 g for 5 days. All the patients were responsive to the treatment with the effectiveness rate of 100%.
(3) Twenty eight patients with complicated urinary tract infections were treated with AC-1370 principally at a daily dose of 2 g for 5 days. The clinical efficacy was evaluated in accordance with the criteria of UTI committee, and was excellent in 6 cases, moderate in 10 cases and poor in 12 cases with the effectiveness rate of 57.1%.
(4) The AC-1370 was more effective for the treatment of pyelonephritis than cystitis in the field of complicated urinary tract infections, and its efficacy for cases with polymicrobial infection or catheter indwelt was rather poor.
(5) No remarkable side effects were observed except for transient nausea during drip infusion of AC-1370 in one case. As for abnormal laboratory findings, slight elevation of GOT in 1 case and of GOT and GPT in 1 case, and slight decrease of WBC in 1 case were noted.
(6) AC-1370 is considered to be effective for the treatment of pyelonephritis caused by bacteria sensitive thereto.
